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This journal is © The Royal Society of CHeterocycle-fused lupane triterpenoids inhibit
Leishmania donovani amastigotes†
Raisa Haavikko,a Abedelmajeed Nasereddin,b Nina Sacerdoti-Sierra,b
Dmitry Kopelyanskiy,b Sami Alakurtti,c Mari Tikka,a Charles L. Jaffe‡b and Jari Yli-
Kauhaluoma*a
The synthesis of heterocyclic betulin derivatives and their activity against Leishmania donovani is reported.
Betulonic acid was used as a versatile intermediate. Several different fused heterocycles were introduced at
the 2,3-position of the lupane skeleton including isoxazole, pyrazine, pyridine, indole and pyrazole rings.
Also the 28-position was modified. Three compounds, 5, 8 and 25, showed low micromolar activity with
IC50 values of 13.2, 4.3 and 7.2 mM, respectively. Compound 8 showed the best activity and selectivity,
and its activity was tested on infected macrophages using a concentration, 5 mM, where no macrophage
toxicity was exhibited. Interestingly, the activity of compound 8 on axenic amastigotes and Leishmania-
infected macrophages was similar.Introduction
Leishmaniasis is a spectrum of diseases caused by over 20
species of protozoan parasites belonging to the genus Leish-
mania. These diseases affect people in more than 88 countries.
There are an estimated 1–2 million new cases every year, 12
million people currently infected, and 350 million people living
in endemic areas at risk.1,2 During the past ten years leish-
maniasis has spread considerably.2 It is transmitted by the bite
of infected female Phlebotomine or Lutzomyia sandies in the
Old World and the New World, respectively.3
There are three major forms of leishmaniasis: cutaneous,
mucocutaneous, and visceral disease.2,4 Cutaneous leishmani-
asis is the mildest form of this disease and is characterized by
skin ulcers on exposed areas at the site of the sand y bite. The
ulcers generally self-heal leaving scars aer a few months to
years. In the mucocutaneous form, which is difficult to treat,
disguring lesions destroy the mucous membranes of the nose,
mouth and throat cavity. Finally, visceral leishmaniasis (VL), the
most severe form of the disease, is fatal if untreated. VL causes
fever, weight loss, anaemia, and enlargement of the spleen andutical Chemistry, University of Helsinki,
014, Helsinki, Finland. E-mail: jari.
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hemistry 2014liver. Several treatments exist for leishmaniasis, but most of
them have adverse effects. Pentavalent antimonials, the rst-
line treatment for leishmaniasis, have lost their efficacy in some
regions endemic for VL,5 and liposomal amphotericin B is
highly expensive. These treatments are administrated by injec-
tion and require clinical supervision or hospitalization. Milte-
fosine, the rst effective orally administrated drug for
leishmaniasis, is contraindicated in women of child-bearing
age due to teratogenic effects.6 Hence, there is an urgent need to
develop new, safe and effective treatments for these diseases.
Betulin is a plentiful naturally occurring lupane-type penta-
cyclic triterpene. Betulinic acid and other betulin derivatives
show antiviral,7 anti-HIV,8 anti-inammatory,9 anti-malarial,10
and anti-tumoral11 effects. Previously our group has shown that
heterocyclic betulin derivatives have an effect against L. dono-
vani amastigotes, which cause VL.12 In this study we describe a
new set of heterocyclic betulin derivatives and their biological
activity against Leishmania donovani amastigotes, as well as the
structure–activity relationships of the compounds.Results and discussion
Chemistry
First, betulin 1 was subjected to Jones oxidation, and the
resulting betulonic acid 2 was used as a key intermediate for the
synthesis of several heterocyclic adducts (Scheme 1). The indole
derivatives 3 and 4 were prepared by the Fischer indole
synthesis in 21–42% yields. Letting betulonic acid react with
ethylenediamine in the presence of sulfur and morpholine gave
lupa-2,20(29)-dieno[2,3-b]pyrazin-28-oic acid 5 in 68% yield.13
This was treated with oxalyl chloride in dichloromethane (DCM)
and the resulting acyl chloride was converted to the primaryMed. Chem. Commun., 2014, 5, 445–451 | 445
Scheme 1 Reagents and conditions: (a) Jones oxidation, Na2Cr2O7,
H2SO4, H2O, acetone, rt, 21 h, 44%; (b) appropriate phenylhydrazine
hydrochloride, HOAc, reflux, 3 h, 21–42%; (c) ethylenediamine, sulfur,
morpholine, reflux, 21 h, 68%; (d) NH2OH$HCl, pyridine, MeOH, reflux,
16 h, 84%; (e) propargylamine, Cu(I)Cl, EtOH, reflux, 17 h, 11%; (f) 1.
oxalyl chloride, DCM, rt, 3 h; 2. aqueous ammonia, DCM, rt, 1 h, quant.;
(g) TFAA, DCM, rt, 20 h, 33%. DCM ¼ dichloromethane, TFAA ¼ tri-
fluoroacetic anhydride.
Scheme 3 Reagents and conditions: (a) benzyl bromide, K2CO3, DMF,
55 C, 22 h, 43%; (b) H2, 10% Pd/C, EtOAc, rt, 72 h, quant.; (c) ethyl
formate, NaH, THF, rt, 22 h, 56%; (d) NH2OH$HCl, HOAc, reflux, 6 h,
































































































View Article Onlineamide 6 quantitatively by aqueous ammonia in chloroform.14 3-
Oximinolup-20(29)-en-28-oic acid 7 was obtained by reuxing
betulonic acid in the presence of NH2OH$HCl and pyridine in
methanol. The oxime 7 was further converted to 4-aza-3-oxo-
homolup-20(29)-en-28-oic acid 8 in 33% yield in the Beckmann
rearrangement reaction by treating it with triuoroacetic
anhydride (TFAA) in DCM. Lupa-2,20(29)-dieno[2,3-b]pyridin-
28-oic acid 9 was obtained from the reaction of betulonic acid
and propargylamine in the presence of Cu(I)Cl in ethanol in
11% yield.15
The corresponding isoxazole 10 and pyrazole 11 derivatives
were synthesized via the 2-hydroxymethylene adduct 12 of
betulonic acid 2 followed by the condensation/cyclization
reaction with NH2OH$HCl16 or H2NNH2$H2O17 in 68% and 80%
yields, respectively (Scheme 2). The carboxyl group of lupa-
2,20(29)-dieno[2,3-d]isoxazol-28-oic acid 10 was converted to the
primary amide functionality 13 as described above in the case of
compound 6.14
20(29)-Dihydrolup-2-en[2,3-d]isoxazol-28-oic acid 14 was
obtained from benzyl betulonate in three steps (Scheme 3).Scheme 2 Reagents and conditions: (a) ethyl formate, NaH, THF, rt,
16 h, 56%; (b) H2NNH2$H2O, p-TsOH, PhMe, 150 C, 17 h, 80%; (c)
NH2OH$HCl, HOAc, reflux, 3 h, 68%; (d) 1. oxalyl chloride, DCM, rt, 1 h;
2. aqueous ammonia, CHCl3, rt, 30 min, quant. THF¼ tetrahydrofuran.
446 | Med. Chem. Commun., 2014, 5, 445–451First, the carbon–carbon double bond of benzyl betulonate was
reduced under a hydrogen atmosphere in the presence of
palladium on carbon in ethyl acetate to give the corresponding
dihydrobetulonic acid in 77% yield. The subsequent Claisen
condensation with ethyl formate produced 2-(hydroxy-
methylene)-3-oxo-20(29)-dihydrolupen-28-oic acid in 56% yield.
Finally, the treatment of the Claisen product with NH2OH$HCl
in acetic acid gave the target 20(29)-dihydrolup-2-en[2,3-d]iso-
xazol-28-oic acid 14 in 90% yield.
28-Hydroxylupa-2,20(29)-dieno[2,3-d]isoxazole 15 was
synthesized from betulin 1 in ve steps (Scheme 4). First, the
betulin C-28 hydroxy group was protected as a tetrahydropyr-
anyl ether 16 in 80% yield, and the resulting THP ether was
oxidized to the THP-protected betulonic alcohol with PCC in
DCM18 in 46% yield. Subsequently, the same cascade of reac-
tions as described above for lupa-2,20(29)-dieno[2,3-d]isoxazol-
28-oic acid 10 was used to produce the isoxazole-fused 28-
O-acetyl triterpene 17 in 26% yield over two steps (Scheme 4). In
acidic conditions of the cyclization reaction the THP protecting
group was cleaved and replaced with the acetoxy group. The
acetoxy group was removed with p-TsOH in methanol in quan-
titative yield. Finally, 28-hydroxylupa-2,20(29)-dieno[2,3-d]iso-
xazole 15 was treated with 2-iodoxybenzoic acid in THF and
DMSO to give 28-oxolupa-2,20(29)-dieno[2,3-d]isoxazole 18 in
51% yield.
Allobetulin 19 was obtained in 25% yield by reuxing betulin
1 in formic acid followed by reuxing the resulting intermediate
formate ester in ethanolic solution of KOH in benzene
(Scheme 5). The indole derivatives of allobetulin 20–21 wereScheme 4 Reagents and conditions: (a) pyridine p-toluenesulfonate,
3,4-dihydro-2H-pyran, DCM, rt, 18 h, 80%; (b) PCC, DCM, rt, overnight,
46%; (c) ethyl formate, NaH, THF, rt, 22 h, 52%; (d) NH2OH$HCl, HOAc,
reflux, 4 h, quant.; (e) p-TsOH, MeOH, reflux, 20 h, quant.; (f) IBX, THF,
DMSO, rt, 3.5 h, 51%. PCC ¼ pyridinium chlorochromate, IBX ¼
2-iodoxybenzoic acid, DMSO ¼ dimethyl sulfoxide.
This journal is © The Royal Society of Chemistry 2014
Scheme 5 Reagents and conditions: (a) formic acid, reflux, 45 min; 1
M KOH in EtOH, benzene, 30 min, 25%; (b) Jones oxidation, 21 h, 88%;

































































































View Article Onlineobtained with the same methodology as described above for
betulonic acid (cf. synthesis of compounds 3 and 4) in 57–63%
yields.
Betulonic aldehyde 22 was obtained from betulin 1 by PCC
oxidation in DCM in 27% yield (Scheme 6). 28-Oxolupa-2,20(29)-
dieno[2,3-b]pyrazine 23 was synthesized in 17% yield using the
same methods as in the preparation of lupa-2,20(29)-dieno[2,3-
b]pyrazin-28-oic acid 5. It was further reacted with NH2OH$HCl
to give 28-oximinolupa-2,20(29)-dien[2,3-b]pyrazine 24 in 77%
yield.
3b-(3-Carboxy-3-methylbutanoyloxy)lup-20(29)-en-28-oic acid
(bevirimat) 25 was synthesized from betulinic acid 26 by
reuxing it in the presence of 2,2-dimethylsuccinic anhydride
and DIPEA in DMF for 2 days in 5% yield (Scheme 7).Biology and structure–activity relationships
Previously we found a set of heterocyclic betulin derivatives to
have promising activity against axenic amastigotes of
L. donovani,12 and based on those results we synthesized a newScheme 6 Reagents and conditions: (a) PCC, DCM, rt, 1 h, 27%; (b)
ethylenediamine, sulfur, morpholine, reflux, 2.5 h, 17%; (c)
NH2OH$HCl, pyridine–EtOH (1 : 3), reflux, 16 h, 77%.
Scheme 7 Reagents and conditions: (a) NaBH4, 2-propanol, rt; (b) 2,2-
dimethylsuccinic anhydride, DIPEA, DMF 170 C, 2 days, 5%. DIPEA ¼
N,N-diisopropylethylamine.
This journal is © The Royal Society of Chemistry 2014set of fused heterocyclic adducts of betulin, betulinic acid and
betulonic acid, and varied substituents at the position C-28 to
explore effects of that position as well. Leishmanicidal activity
of the modied compounds was assayed using the alamarBlue
(AbD Serotec, Oxford, UK) viability assay on axenic amastigotes
of L. donovani (Table 1).
Primary screening was performed at 50 mM concentration
and compounds showing >70% inhibition were assayed at
15 mM concentration and nally most potent derivatives at 5 mM
concentration (Table 1).
In the series of A-ring fused isoxazoles, the betulin-derived
compound 15 had 57% inhibition of the growth at 50 mM
concentration. The betulinic acid-derived isoxazole 10 inhibits
96% at 50 mM and 16% at 15 mM. Interestingly, the dihy-
drobetulinic acid-derived isoxazole 14 had only 3% inhibition at
50 mM. In our earlier studies we found a similar effect, but not
this strong, between betulonic acid and dihydrobetulonic
acid.19 The primary amide derivative of the betulinic acid-
derived isoxazole 13 inhibits 84% of the growth at 50 mM
concentration, but only 17% at 15 mM concentration. On the
other hand, the betulinic aldehyde-derived isoxazole 18 has
lower activity (34%) at 50 mM but slightly better activity (21%) at
15 mM concentration compared to 13. This may be due to
solubility, as the aldehyde might not be completely soluble
at high concentration. The least active isoxazole derivative,
28-O-acetylbetulin-derived isoxazole 17 inhibited only 6% of the
growth at 50 mM concentration. It has been suggested that the
carboxyl group in the triterpenoid skeleton enhancesTable 1 Activity of the compounds against axenic amastigotes of
Leishmania donovani
Compound
% Inhibition  s. e.b
IC50 mM
 s. e.c50 mM
15 mM
(mM  s. e.) 5 mM
2 98.6  0.1 45.9  0.7 — —
3 23.4  2.2 27.4  2.4 5.0  4.4 —
4 29.3  4.1 17.5  2.7 14.0  2.0 —
5 92.7  0.1 79.7  0.4 20.3  0.4 13.2  1.4
6 94.9  0.2 35.2  1.4 — —
8 98.2  0.1 75.2  1.1 52.0  1.2 4.3  0.4
9 87.9  0.5 25.6  1.5 — —
10 95.7  0.3 15.6  1.0 — —
11 60.2  0.7a — — —
13 84.3  0.8 16.7  2.0 — —
14 2.4  3.4 — — —
15 56.9  0.4 — — —
17 6.1  3.7 — — —
18 34.2  2.0 21.1  1.1 — —
20 19.8  2.4 18.5  0.8 — —
21 6.8  0.7 10.2  4.1 0.2  1.3 —
24 2.8  4.5 — — —
25 100.4  0.1 69.1  3.1 59.0  0.4 7.2  0.2
26 61.1  0.6a — — —
Amphotericin B — — 99.9  0.3 —
Medium alone 0.0  4.6 1.5  3.8 0.0  0.9 —
a Precipitates at 50 mM, see crystals. b Average inhibition of triplicates.
c Average of two experiments; amphotericin B is a positive control and
was tested at 1 mM.
Med. Chem. Commun., 2014, 5, 445–451 | 447
Table 2 Toxicity for THP-1 macrophages, and activity against Leish-




(mM  s. e.) SIb
% inhibition  s. e. of
parasites in iMFc
5 mM
8 55.5  1.8 12.9 54.0  4.8
25 54.0  1.7 7.5 nd
Amphotericin
B
nd nd 96.7  0.7
a Average of two experiments. b Selectivity index ¼ IC50 THP-1/IC50
axenic amastigotes. c Average of three experiments; nd – not done;
amphotericin B is a positive control and was tested on infected
































































































View Article Onlinethe observed antiprotozoal effects.20 However, among these
A-ring fused isoxazole derivatives of betulin, the compounds 18
and 13 were more active than the betulinic acid-derived iso-
xazole 10. All isoxazole derivatives were less active than betu-
lonic acid 2 (99% at 50 mM, 46% at 15 mM).
The A-ring fused pyrazine derivative of betulinic acid 5
showed 93% at 50 mM, 80% at 15 mM, and 20% inhibition at 5 mM
concentration, whereas for the corresponding primary amide 6,
we observed inhibition of 95% at 50 mM, and 35% at 15 mM
concentration, and for its 28-oximino derivative 24 only 3% at 50
mM. Interestingly, the A-ring fused pyridine derivative of betu-
linic acid 9 inhibited 88% at 50 mM, but only 26% at 15 mM
concentration. Here, with pyrazine derivatives, we could see the
importance of the carboxyl group for antileishmanial activity.
The A-ring fused 50-methoxyindole derivative of betulinic
acid 4 was the most active indole derivative. At 5 mM, the lowest
concentration tested, inhibition was 14%, whereas the corre-
sponding unsubstituted indole derivative 3 inhibited only 5%.
Also with the related indole derivatives the importance of the
carboxyl group can be seen as the A-ring fused indole derivative
of allobetulin 20 and the corresponding 50-uoroindole deriva-
tive 21 did not have activity at all. One factor affecting this might
be the reduced solubility; allobetulin derivatives are not that
soluble under the assay conditions. In addition, the A-ring fused
pyrazole derivative of betulinic acid 11 and betulinic acid 26
precipitated at 50 mM in these assays.
4-Aza-3-oxohomobetulinic acid 8 displayed very good activity
(98%) at 50 mM concentration and even at 5 mM concentration
(inhibition 52%), whereas the A-ring fused pyrazole derivative of
betulinic acid 11 displayed moderate 60.2% inhibition at 50 mM
concentration. In addition, potent anti-HIV betulinic acid
derived compound 25, bevirimat, displayed very good inhibi-
tion: 100% inhibition at 50 mM concentration and 59% at 5 mM
concentration. The best compounds aer primary screening
were compounds 5, 8 and 25 that signicantly inhibited para-
site growth when tested at lower concentrations. The IC50 values
for 5, 8 and 25 were 13.2, 4.3 and 7.2 mM, respectively, with
compound 8 showing the best activity. Cytotoxicity IC50 values
of 8 and 25 against THP-1 cell line were 55.5 and 54.0 mM,
respectively. Compound 25 (bevirimat) showed the highest
activity among the compounds tested in this study. It showed
100% inhibition at 50 mM, 69% at 15 mM, and 59% at 5 mM.
Interestingly, bevirimat 25 also showed good activity against
HIV-infected patients in a recent phase II study.21 Only 4-aza-3-
oxohomobetulinic acid 8 showed a similar level of activity with
98% inhibition at 50 mM, 75% at 15 mM, and 52% at 5 mM. The
third most active compound was the A-ring fused pyrazine
derivative of betulinic acid 5. Cytotoxicity (Table 2) using the
human macrophage cell line THP-1 was determined for 8 and
25, and found to be similar (IC50 ca. 50 mM) for both
compounds. Compound 8 had the best selectivity index
(IC50 THP-1/IC50 axenic amastigotes; SI ¼ 12.9), and its activity
was tested on L. donovani-infected macrophages at low 5 mM
concentration, where no macrophage toxicity was observed.
Interestingly, activity of the compound 8 against Leishmania
infected macrophages (54.0  4.8% inhibition) was similar to
that seen for axenic amastigotes (52.0  1.2% inhibition).448 | Med. Chem. Commun., 2014, 5, 445–451Experimental section
Chemistry
10H-Lupa-2,20(29)-dieno[3,2-b]indol-28-oic acid (3). Betu-
lonic acid (0.10 g, 0.22 mmol) and the corresponding phenyl-
hydrazine hydrochloride (0.35 g, 0.24 mmol) were dissolved in
acetic acid (10 mL) and reuxed (130 C) for 3 h. Water was
added and the resulting mixture was extracted with Et2O. The
organic phase was washed with water and brine, dried over
anhydrous Na2SO4, and the solvents were evaporated. The crude
product was puried by SiO2 column chromatography (25–50%
EtOAc–n-hexane) to give a yellowish solid (49 mg, 42%). 1H NMR
(300 MHz, CDCl3) d 7.71 (s, 1H), 7.37 (m, 1H), 7.29 (m, 1H), 7.08
(m, 2H), 4.79 (s, 1H), 4.65 (s, 1H), 3.08 (m, 1H), 2.83 (d, J ¼ 15.0
Hz, 1H), 2.38–2.09 (m, 4H), 1.73 (s, 3H), 1.68–1.31 (m, 12H), 1.28
(s, 3H), 1.17 (s, 3H), 1.05 (s, 3H), 1.04 (s, 3H), 0.88 (s, 3H); 13C
NMR (75 MHz, CDCl3) d 181.7, 150.4, 140.9, 136.2, 128.4, 121.0,
119.0, 117.9, 110.3, 109.8, 107.1, 56.5, 53.3, 49.4, 49.4, 47.0, 42.5,
40.8, 38.7, 38.3, 37.1, 34.1, 33.6, 32.2, 31.6, 30.9, 29.9, 25.7, 23.1,
22.6, 21.5, 19.4, 19.2, 16.3, 15.9, 14.8; FTIR (n, cm1): 738, 885,
907, 1459, 1693, 2873, 2843; HRMS: m/z calcd for C36H50NO2
528.3842, found 528.3838 [M + H]+. NMR spectral data are
consistent with those previously reported.22
Lupa-2,20(29)-dieno[2,3-b]pyrazin-28-oic acid (5). A mixture
of betulonic acid (0.20 g, 0.44 mmol), 1,2-diaminoethane
(130 mg, 2.0 mmol), sulfur (130 mg, 4.1 mmol) and morpholine
(4 mL) was reuxed for 21 h. Water was added and the resulting
mixture was extracted with CH2Cl2. The organic phase was
washed with 1 M hydrochloric acid, water, a saturated aqueous
solution of NaHCO3, water and brine, dried over anhydrous
Na2SO4 and evaporated. The crude product was puried by SiO2
column chromatography (20–50% EtOAc–n-hexane) to give a
white crystalline solid (147 mg, 68%).13 1H NMR (300 MHz,
CDCl3) d 8.42 (d, J ¼ 2.4 Hz, 1H), 8.29 (d, J ¼ 2.4 Hz, 1H), 4.76
(s, 1H), 4.64 (s, 1H), 3.05 (m, 2H), 2.46 (d, J ¼ 16.5 Hz, 1H), 2.29
(m, 2H), 1.30 (s, 3H), 1.72 (s, 3H), 1.27 (s, 3H), 1.04 (s, 3H), 1.03
(s, 3H), 0.81 (s, 3H); 13C NMR (75 MHz, CDCl3) d 181.5, 160.0,
151.0, 150.5, 142.6, 141.5, 110.0, 56.6, 53.2, 49.4, 49.0, 48.7, 47.1,
42.7, 40.8, 39.7, 38.7, 37.3, 37.0, 33.6, 32.4, 31.7, 30.8, 30.0, 25.7,
24.2, 21.6, 20.3, 19.7, 16.4, 15.9, 14.9; FTIR (n, cm1): 878, 1107,
































































































View Article Online491.3638, found 491.3637 [M + H]+. 1H NMR spectral data are
consistent with those previously reported.23
Lupa-2,20(29)-dieno[2,3-d]pyrazin-28-amide (6). A mixture of
lupa-2,20(29)-dieno[2,3-d]pyrazin-28-oic acid (141 mg, 0.28
mmol), oxalyl chloride (44 mg, 0.34 mmol), and a drop of DMF
in dry THF (10 mL) was stirred at room temperature for 2 h. The
solvent was evaporated, and the residue was dissolved in EtOAc.
The organic phase was washed with a saturated aqueous solu-
tion of NaHCO3, water and brine, dried over anhydrous Na2SO4
and evaporated. The resulting crude lupa-2,20(29)-dieno[2,3-b]-
pyrazin-28-oyl chloride was dissolved in CHCl3 (5 mL), and a
water solution of 25% ammonia (2 mL) was added to the
mixture. The resulting solution was stirred at room temperature
for 30 min and evaporated to dryness to give a white crystalline
solid (137 mg, quant.).14 1H NMR (300 MHz, CDCl3) d 8.46
(s, 1H), 8.29 (d, J ¼ 2.4 Hz, 1H), 5.30 (br s, 2H), 4.77 (s, 1H), 4.64
(s, 1H), 3.72 (q, J ¼ 7.0 Hz, 1H), 3.12 (d, J ¼ 17.0 Hz, 2H), 2.67–
2.40 (m, 2H), 2.08–1.74 (m, 5H), 1.71 (s, 3H), 1.67–1.35 (m, 13H),
1.31 (s, 3H), 1.30 (s, 3H), 1.04 (s, 3H), 1.03 (s, 3H), 0.82 (s, 3H);
13C NMR (75 MHz, CD3OD) d 182.4, 161.4, 152.3, 152.0, 143.8,
142.3, 110.0, 57.1, 54.3, 51.2, 50.1, 48.1, 43.7, 41.9, 40.62, 39.4,
39.1, 37.9, 34.6, 34.3, 31.9, 31.8, 30.7, 27.0, 24.4, 22.8, 21.2, 19.6,
16.6, 16.3, 15.0; FTIR (n, cm1): 886, 1107, 1184, 1402, 1665,
2869, 2948, 3044, 3129; HRMS: m/z calcd for C32H48N3O
489.3797, found 490.3796 [M + H]+.
4-Aza-3-oxohomolup-20(29)-en-28-oic acid (8). A mixture of
betulonic acid (0.20 g, 0.44 mmol), hydroxylamine hydrochlo-
ride (290 mg, 4.2 mmol), dry pyridine (5 mL) and methanol
(8 mL) was reuxed for 16 h. Water was added, and the
precipitated 3-oximinolup-20(29)-en-28-oic acid 7 was ltered
and collected (173 mg, 84%). 3-Oximinolup-20(29)-en-28-oic
acid 7 (86 mg, 0.18 mmol) was dissolved in CH2Cl2 (5 mL), and
the resulting solution cooled to the ice-water bath temperature.
Triuoroacetic anhydride (1.0 mL, 7.1 mmol) was added to this
solution and the resulting mixture was stirred at room temper-
ature for 20 h. The reaction mixture was washed with water, a
saturated aqueous solution of NaHCO3 and brine, dried over
anhydrous Na2SO4, and evaporated. The crude product was
puried by SiO2 column chromatography (0–10% MeOH–
CH2Cl2) to yield a white crystalline solid (28mg, 33%).16
1H NMR
(300 MHz, CDCl3) d 6.39 (s, 1H), 4.73 (s, 1H), 4.61 (s, 1H), 2.99
(m, 1H), 2.59–2.41 (m, 1H), 2.42–2.15 (m, 4H), 2.13–1.94 (m, 2H),
1.69 (s, 3H), 1.57–1.33 (m, 12H), 1.31 (s, 3H), 1.23 (s, 3H), 1.03
(s, 3H), 0.98 (s, 3H), 0.97 (s, 3H); 13C NMR (75 MHz, CDCl3) d
181.3, 177.5, 150.6, 109.9, 56.7, 56.5, 56.5, 53.2, 51.2, 49.3, 47.7,
42.8, 41.0, 40.5, 39.5, 38.8, 37.3, 33.9, 33.4, 32.3, 32.0, 30.8, 29.8,
27.2, 26.1, 22.7, 22.3, 19.6, 18.5, 16.1, 14.8, 14.7; FTIR (n, cm1):
731, 883, 1185, 1374, 1454, 1628, 1691, 2938, 3250; HRMS: m/z
calcd for C30H48NO3 470.3634, found 470.3630 [M + H]
+.
10H-Lup-20(29)-eno[2,3-b]pyridin-28-oic acid (9). A mixture
of betulonic acid (100 mg, 0.22 mmol), propargylamine (24 mg,
0.44 mmol), Cu(I)Cl (5.0 mg, 0.050 mmol) and ethanol (5 mL)
was reuxed for 17 h. The resulting solution was ltered,
evaporated, and the crude product was puried by SiO2 column
chromatography (10–20% EtOAc–n-hexane) to yield a crystalline
solid (12 mg, 11%).15 1H NMR (300 MHz, CDCl3) d 8.47 (m, 1H),
7.27 (m, 1H), 7.02 (dd, J ¼ 7.6, 4.8 Hz, 1H), 4.75 (s, 1H), 4.62This journal is © The Royal Society of Chemistry 2014(s, 1H), 3.10 (m, 1H), 2.74 (d, J¼ 15.9 Hz, 1H), 2.32 (m, 3H), 2.03
(m, 2H), 1.70 (s, 3H), 1.67–1.36 (m, 13H), 1.32 (s, 3H), 1.27
(s, 3H), 1.02 (s, 3H), 0.99 (s, 3H), 0.78 (s, 3H). 13C NMR (75 MHz,
CDCl3) d 180.3, 163.6, 150.8, 146.8, 138.4, 130.3, 121.1, 109.7,
56.6, 53.8, 49.5, 49.0, 47.12, 46.1, 42.7, 40.8, 39.6, 38.7, 37.2,
36.4, 33.7, 32.5, 31.6, 30.9, 30.0, 25.8, 24.2, 21.7, 20.4, 19.6, 16.0,
15.9, 14.8; FTIR (n, cm1): 1012, 1045, 1110, 1132, 1184, 1457,
2856, 2927, 2959; HRMS: m/z calcd for C33H48NO2 490.3685,
found 490.3683 [M + H]+.
2-(Hydroxymethylene)-3-oxolup-20(29)-en-28-oic acid (12). A
mixture of betulonic acid (0.200 g, 0.440 mmol), NaH (60%
dispersion in mineral oil, 0.490 g, 12.8 mmol) and dry THF
(10 mL) was cooled to the ice-water bath temperature. To this
solution ethyl formate (0.749 g, 10.1 mmol) was added, the
resulting mixture was warmed to room temperature and stirred
overnight. A saturated aqueous solution of NH4Cl was added,
and the resulting mixture was extracted with EtOAc, washed
with water and brine, dried over anhydrous Na2SO4, and evap-
orated. The crude product was puried by SiO2 column chro-
matography (10–50% EtOAc–n-hexane) to yield a white
crystalline solid (127 mg, 60%). 1H NMR (300 MHz, CDCl3) d
14.85 (d, J ¼ 2.6 Hz, 1H), 9.88 (br s, 1H), 8.58 (d, J ¼ 2.6 Hz, 1H),
4.75 (s, 1H), 4.62 (s, 1H), 3.01 (m, 1H), 2.31 (m, 3H), 2.09–1.80
(m, 3H), 1.70 (s, 3H), 1.46 (m, 16H), 1.18 (s, 3H), 1.08 (s, 3H),
1.00 (s, 3H), 0.99 (s, 3H), 0.83 (s, 3H).
Lupa-2,20(29)-dieno[2,3-d]isoxazol-28-oic acid (10). A
mixture of 2-(hydroxymethylene)-3-oxolup-20(29)-en-28-oic acid
(0.091 g, 0.18 mmol), hydroxylamine hydrochloride (0.036 g,
0.52 mmol) and acetic acid (10 mL) was reuxed for 3 h. Water
was added, and the resulting mixture was extracted with EtOAc,
washed with a saturated aqueous solution of NaHCO3, water,
and brine, dried over anhydrous Na2SO4, and evaporated to give
a white solid (59 mg, 68%).12 1H NMR (300 MHz, CDCl3) d 10.92
(br s, 1H), 7.97 (s, 1H), 4.75 (s, 1H), 4.63 (s, 1H), 3.09–2.92
(m, 1H), 2.47 (d, J ¼ 15.1 Hz, 1H), 2.36–2.19 (m, 3H), 2.06–1.88
(m, 3H), 1.70 (s, 3H), 1.60–1.33 (m, 15H), 1.28 (s, 3H), 1.19
(s, 3H), 1.01 (s, 3H), 0.99 (s, 3H), 0.81 (s, 3H); 13C NMR (75 MHz,
CDCl3) d 181.3, 173.0, 150.3, 150.3, 109.8, 108.9, 56.4, 53.6, 49.2,
49.1, 46.9, 42.5, 40.8, 39.0, 38.5, 37.0, 35.9, 34.8, 33.4, 32.1, 30.6,
29.8, 28.7, 25.5, 21.4, 21.2, 19.4, 18.8, 16.1, 15.8, 14.7; FTIR
(n, cm1): 733, 881, 1181, 1375, 1454, 1695, 2875, 2940; HRMS:
m/z calcd for C31H46NO3 480.3478, found 480.3478 [M + H]
+.
NMR spectral data are consistent with those previously
reported.24
10H-Lup-20(29)-eno[3,2-c]pyrazol-28-oic acid (11). A mixture
of 2-(hydroxymethylene)-3-oxolup-20(29)-en-28-oic acid (53 mg,
0.11 mmol), hydrazine hydrate (16 mg, 0.31 mmol) and toluene
(20 mL) was reuxed at 150 C under Dean–Stark conditions
overnight. Aer cooling the reaction mixture to room temper-
ature, the solvent was evaporated, and the resulting crude
product was puried by SiO2 column chromatography (1–10%
EtOAc–n-hexane) to give a white crystalline solid (42 mg, 80%).17
1H NMR (300 MHz, CD3OD) d 7.16 (s, 1H), 4.72 (s, 1H), 4.60
(s, 1H), 3.04 (m, 1H), 2.64 (d, J¼ 14.8 Hz, 1H), 2.46–2.18 (m, 2H),
1.91 (m, 2H), 1.70 (s, 3H), 1.65–1.33 (m, 11H), 1.26 (s, 3H), 1.17
(s, 3H), 1.04 (s, 3H), 1.03 (s, 3H), 0.80 (s, 3H); 13C NMR (75 MHz,
































































































View Article Online49.4, 49.2, 47.3, 42.5, 40.8, 38.6, 36.9, 36.5, 33.6, 33.4, 32.1, 30.6,
30.1, 29.8, 25.8, 22.8, 21.4, 19.1, 18.4, 15.3, 15.2, 14.0; FTIR
(n, cm1): 883, 960, 1086, 1184, 1370, 1452, 1643, 1695, 2869,
2943; m/z calcd for C31H47N2O2: 479.3638; found 479.3638 [M +
H]+. NMR spectral data are consistent with those previously
reported.24Biology
L. donovani (MHOM/SD/1962/1S-Cl2d) was used in all bioassays.
Axenic amastigotes were grown at 37 C in a 5% CO2 incubator
as described in complete RPMI 1640 containing 20% fetal calf
serum, pH 5.5. Screening of the compounds for leishmanicidal
activity was carried out using the alamarBlue (AbD Serotec,
Oxford, UK) viability assay similar to that reported for leish-
manial promastigotes. Standardization and optimization of the
assay for axenic amastigotes has been described elsewhere.25
Compounds to be assayed were diluted to twice the nal
concentration used in the assays in the complete amastigote
medium, containing 1% DMSO, and were aliquoted in triplicate
(125 mL per well) into 96-well at-bottom plates (Nunc, Roskilde,
Denmark). IC50 was determined using serial two-fold dilutions
of the test compounds from 50 to 0.4 mM. Amastigotes (5.0 105
cells mL1; 125 mL per well) were added to each well and incu-
bated for 24 h at 37 C in a 5% CO2 incubator. The alamarBlue
viability indicator was added (25 mL per well) and the plates
incubated for an additional 24 h at which time the uorescence
(lex ¼ 544 nm; lem ¼ 590 nm) was measured in a microplate
reader (Fluoroskan Ascent FL, Finland). Complete medium
both with and without DMSO was used as negative controls (0%
inhibition of amastigote growth). Amphotericin B (Sigma-
Aldrich, St Louis MO), a drug used to treat VL, was included as a
positive control on each plate and gave >90% inhibition of
parasite growth at 1 mM. Toxicity was measured on the human
leukaemia monocyte cell line (THP-1 6.4  104 cells per well)
using the alamarBlue viability indicator as previously
described.26 IC50 was determined using serial two-fold dilutions
of the test compounds in triplicate from 500 to 0.25 mM. Inhi-
bition of intracellular amastigote growth in infected THP-1 cells
(1.0  105 cells per well) was carried out using transgenic
Ld:pSSU-int/LUC promastigotes that express luciferase essen-
tially as previously described.26 Amphotericin B (1 mM) was
included as a positive control on each plate. Complete medium
both with and without DMSO was used as negative controls.
Calculation of the IC50's and statistical analysis were carried out
using GraphPad Prism Version 6.0b (GraphPad Soware, Inc.
San Diego, CA).Conclusions
A set of betulin, betulinic acid and dihydrobetulinic acid
derivatives, including eight new A-ring fused heterocycles, was
synthesized and tested against L. donovani. Two heterocyclic
compounds 5, 8, and potent anti-HIV drug candidate 25 had
signicant inhibition on parasite growth even at 5 mM concen-
tration. Compound 8 had the best selectivity index, and showed
similar good activity on Leishmania-infected macrophages and450 | Med. Chem. Commun., 2014, 5, 445–451axenic amastigotes. Further improvement and optimization are
needed to get more potent betulin derivatives against
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